Biotechnology
China Biologic Products to Report Second Quarter 2019 Financial Results
BEIJING, July 26, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its second quarter 2019 financial resu...
2019-07-27 04:30
10364
LISCure Biosciences Has Completed Seed Funding of USD 5 Million for Bacteria-mediated Immunotherapy R&D Enhancement
SEOUL, South Korea, July 25, 2019 /PRNewswire/ -- LISCure Biosciences, a biotech company that researches and develops bacteria-mediated immunotherapy, has succeeded in attracting5 million USD of seed funding investment. NHN Investment, Shinhan Investment, and KB Securities have participated in th...
2019-07-25 21:00
2229
Penta and CROMSOURCE Announce Their Partnership to Improve Paediatric Drug Development
VERONA, Italy, July 25, 2019 /PRNewswire/ -- Penta ID Innovation, a recently established SMO stemmed from the Penta Global Paediatric Research Network, and CROMSOURCE, an international contract research organization (CRO) providing a comprehensive portfolio of services to the pharmaceutical, biot...
2019-07-25 19:00
3367
Mirae Asset Launches China Biotech and Cloud Computing themed ETFs in Hong Kong
HONG KONG, July 25, 2019 /PRNewswire/ -- Mirae Asset Global Investments (Hong Kong) Limited today is pleased to announce the launch of its 'Mirae Asset Horizons China Biotech ETF' and 'Mirae Asset Horizons China Cloud Computing ETF' inHong Kong, allowing investors to gain exposure to the vast pot...
2019-07-25 09:00
3185
Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock
AUSTIN, Texas, July 24, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a further strengthening of its balance sheet with an existing investor exercising the balance of its warrant to purchase$4.8 million in aggregate amount of shares of our common stock...
2019-07-25 04:05
9664
Global Cord Blood Corporation Files Its Annual Report on Form 20-F
HONG KONG, July 24, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual ...
2019-07-24 04:16
11177
WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections
SHANGHAI, July 23, 2019 /PRNewswire/ -- STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its Analytical Service Unit (ASU) inShanghai and active pharmaceutical ingredient (API) process R&D and manufacturing facility in Changzhou, have successfully passed two...
2019-07-23 12:48
3435
Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center
SYDNEY, July 22, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) inNew York, NY will investigate the potential use of Kazia's investigational ne...
2019-07-22 09:08
3802
Ascentage Pharma to Initiate Phase Ib Study of HQP1351 in Tyrosine Kinase Inhibitors -resistant Chronic Myeloid Leukemia Patients in the US
SUZHOU, China and ROCKVILLE, Md., July 22, 2019 /PRNewswire/ -- Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the company was notified by the U.S. Food ...
2019-07-22 07:00
3064
Kazia calls for greater awareness of the deadliest brain cancer in the US
SYDNEY, July 17, 2019 /PRNewswire/ -- This Glioblastoma Awareness Day, Australian oncology-focused biotech company, Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA), calls for greater awareness of the most lethal brain cancer in the US. Glioblastoma (GBM) is the most common, complex, treatment ...
2019-07-17 20:00
7794
Menarini Silicon Biosystems Launches VRNxT Volume Reduction Instrument
BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., July 17, 2019 /PRNewswire/ -- Menarini Silicon Biosystems, the pioneer of liquid biopsy and rare cell technologies, announced that it will launch the new VRNxT(TM), a volume reduction instrument optimized to remove manual sample volume reduction steps i...
2019-07-17 08:15
3532
Hummingbird Bioscience Closes Extended Series A Financing To Advance Clinical Pipeline
SINGAPORE, July 10, 2019 /PRNewswire/ -- Hummingbird Bioscience, a Singapore founded biotech company focused on the discovery and development of novel antibody-based therapeutics, today announced the successful completion of an extended Series A financing round. The round was led by Heritas Capit...
2019-07-10 15:09
2880
Accutest Biologics Private Limited (ABPL) Receives the Prestigious OECD-Good Laboratory Practice (GLP) Certification, a First-of-its-kind in India
MUMBAI, India, July 9, 2019 /PRNewswire/ -- India-based Accutest Biologics Private Limited (ABPL), a leading CRO for high-quality Biochemical characterization and Bioanalytical services supporting preclinical and clinical development of Biologics and Biosimilars, has received the prestigious OEC...
2019-07-09 14:30
2709
ISTH Announces Launch Of New Global Education Initiative In Gene Therapy For Hemophilia
MELBOURNE, Australia, July 6, 2019 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH) is pleased to announce the official launch ofGene Therapy in Hemophilia: An ISTH Education Initiative. This landmark launch, the first of its kind in hemophilia, will take place duri...
2019-07-06 06:00
3410
NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study
LUND, Sweden, 4 July 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study with KL1333, NeuroVive's candidate drug for chronic treatment of genetic mitochondri...
2019-07-04 21:05
8635
New England Biolabs®, Inc. opens eighth subsidiary in Australia
IPSWICH, Massachusetts, July 4, 2019 /PRNewswire/ -- New England Biolabs (NEB® ), a world leader in the production of reagents for the life science industry, extended its global subsidiary network with the opening of New England Biolabs Australia Pty Ltd. Australia's Life Sciences industry is hom...
2019-07-03 22:00
2256
Gilead Sciences Announces Launch of Asia Pacific Rainbow Grant 2019
HONG KONG, July 3, 2019 /PRNewswire/ -- Gilead Sciences, Inc. today announced the launch of the 2019 Gilead Asia Pacific Rainbow Grant program, a grant initiative that supports community-led programs for people living with HIV in theAsia Pacific region. Non-governmental or advocacy organizations ...
2019-07-03 18:13
2769
A2A Pharmaceuticals Appoints Dr. Sotirios Stergiopoulos Chief Executive Officer
NEW YORK, July 3, 2019 /PRNewswire/ -- A2A Pharmaceuticals Inc. (A2A), a biotechnology company committed to the advancement of innovative scientific research and new therapeutic agents, today announced the appointment of Dr. Sotirios G. Stergiopoulos as President and Chief Executive Officer. He ha...
2019-07-03 04:28
2658
Cardiac Dimensions Reaches 1,000 Implants Of Carillon® System, A Minimally Invasive Treatment For Functional Mitral Regurgitation
KIRKLAND, Washington, July 1, 2019 /PRNewswire/ -- Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the Carillon Mitral Contour System® has been implanted in 1,0...
2019-07-01 19:10
1428
WuXi AppTec Named One of MIT Technology Review's 50 Smartest Companies
SHANGHAI, June 29, 2019 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announces that it has been selected as one of MIT Technology Review's 50 Smartest Companies (TR50) for 2019. WuXi was chosen for its ded...
2019-06-29 13:26
10150
Week's Top Stories
Most Reposted
Another 'Reason to Travel': Agoda and Singapore Tourism Board Renew Partnership to Boost Travel to Singapore
[Picked up by 350 media titles]
2024-06-19 11:00
MIFB 2024 ENLISTS F&B EXPERTS TO SPEAK ON THE LATEST IN INDUSTRY TRENDS AND THE FUTURE OF FOOD
[Picked up by 335 media titles]
2024-06-20 16:24
New Study Finds Cybersecurity as Top Concern Among Automotive Manufacturers
[Picked up by 317 media titles]
2024-06-19 08:05k-ID Closes $45 Million Series A from Andreessen Horowitz and Lightspeed Venture Partners to Set a New Global Benchmark for Age-appropriate Gaming Experiences
[Picked up by 317 media titles]
2024-06-25 21:00
THEIR ROYAL HIGHNESSES THE DUKE AND DUCHESS OF EDINBURGH CELEBRATE THE GRAND OPENING OF THE PENINSULA LONDON, BELGRAVIA
[Picked up by 313 media titles]
2024-06-19 11:38
Most Read
Another 'Reason to Travel': Agoda and Singapore Tourism Board Renew Partnership to Boost Travel to Singapore
2024-06-19 11:00
15576
MIFB 2024 ENLISTS F&B EXPERTS TO SPEAK ON THE LATEST IN INDUSTRY TRENDS AND THE FUTURE OF FOOD
2024-06-20 16:24
13163
New Study Finds Cybersecurity as Top Concern Among Automotive Manufacturers
2024-06-19 08:05
9412
